Dexcom Inc is a leading company specializing in continuous glucose monitoring systems for individuals with diabetes. Their innovative technology enables users to track glucose levels in real time through a small sensor placed under the skin, eliminating the need for traditional fingerstick testing. The company's products empower patients and healthcare providers to make informed decisions regarding diabetes management, enhancing the quality of life for those living with the condition. By integrating advanced software and mobile applications, Dexcom's systems deliver essential insights and alerts, contributing to better health outcomes for users.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Series D funding, with ŌURA now valued at more than $5 billion.
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.
Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest Form 13F on Thursday and disclosed its trading activity from the prior quarter.
This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest.
Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week’s pivotal earnings releases from five of the “Magnificent Seven” stocks.
